<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kuros Biosciences Ag — News on 6ix</title>
<link>https://6ix.com/company/kuros-biosciences-ag</link>
<description>Latest news and press releases for Kuros Biosciences Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kuros-biosciences-ag" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361b6a78dffbe2df13f2aa.webp</url>
<title>Kuros Biosciences Ag</title>
<link>https://6ix.com/company/kuros-biosciences-ag</link>
</image>
<item>
<title>Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-51percent-year-over-year-increase-in-sales-in-the-first-three-months-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-51percent-year-over-year-increase-in-sales-in-the-first-three-months-of-2026</guid>
<pubDate>Tue, 14 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million)Direct MagnetOs™ product sales increased by 51% to USD 42.9 million (Q1 2025: USD 28.4 million)Group EBITDA reached USD 2.9 million (Q1 2025: EBITDA of USD 2.0 million)Group adjusted EBITDA* amounted to USD 5.7 million, equaling a marg</description>
</item>
<item>
<title>Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-delivers-72percent-year-over-year-sales-growth-reaching-usd-1461-million-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-delivers-72percent-year-over-year-sales-growth-reaching-usd-1461-million-for-2025</guid>
<pubDate>Tue, 10 Mar 2026 06:00:00 GMT</pubDate>
<description>Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total Medical Device sales rose by 72%, or USD 60.9 million, to USD 146.1 million (2024: USD 85.2 million)Direct MagnetOs™ sales increased by 71% to USD 143.9 million (2024: USD 84.3 million)Total Group EBITDA reached USD 12.4 million (2024: USD 2.4 million)Total Group adjusted EBITDA* arrived at USD 19.6 million,</description>
</item>
<item>
<title>Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-investor-octavian-baader-060000908</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-investor-octavian-baader-060000908</guid>
<pubDate>Tue, 13 Jan 2026 06:00:00 GMT</pubDate>
<description>Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™, which are going to be pr</description>
</item>
<item>
<title>Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-announces-enrollment-first-060000594</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-announces-enrollment-first-060000594</guid>
<pubDate>Tue, 02 Dec 2025 06:00:00 GMT</pubDate>
<description>Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlle</description>
</item>
<item>
<title>Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-present-piper-sandler-060000196</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-present-piper-sandler-060000196</guid>
<pubDate>Wed, 26 Nov 2025 06:00:00 GMT</pubDate>
<description>Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2–4, 2025 at The Lotte New York Palace in New York City. The Company’s presentation will highlight continued commercial momentum, clinical advancement across the MagnetOs portfolio,</description>
</item>
<item>
<title>Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-increases-annual-guidance-050000037</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-increases-annual-guidance-050000037</guid>
<pubDate>Thu, 16 Oct 2025 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million)EBITDA for the G</description>
</item>
<item>
<title>Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-debuts-commercial-launch-050000328</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-debuts-commercial-launch-050000328</guid>
<pubDate>Tue, 30 Sep 2025 05:00:00 GMT</pubDate>
<description>Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros booth and</description>
</item>
<item>
<title>Kuros statement on media inquiry concerning former Board member</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-statement-media-inquiry-concerning-163000424</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-statement-media-inquiry-concerning-163000424</guid>
<pubDate>Thu, 18 Sep 2025 16:30:00 GMT</pubDate>
<description>Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros statement on media inquiry concerning former Board member Schlieren (Zurich), Switzerland, September 18, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, has become aware of a possible imminent publication in a Dutch financial media outlet regarding the recent resignation of Albert Arp, a former member of the company’s Board of Directors. Kuros has received inquirie</description>
</item>
<item>
<title>Kuros Biosciences announces changes in the Board of Directors</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-announces-changes-board-050000224</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-announces-changes-board-050000224</guid>
<pubDate>Thu, 04 Sep 2025 05:00:00 GMT</pubDate>
<description>Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, announces that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley</description>
</item>
<item>
<title>Kuros Biosciences Reports First Half of 2025 Results</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-first-half-050000414</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-first-half-050000414</guid>
<pubDate>Thu, 14 Aug 2025 05:00:00 GMT</pubDate>
<description>Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million)Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million)The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024Total Group EBITDA reach</description>
</item>
<item>
<title>Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-launches-magnetos-mis-050000974</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-launches-magnetos-mis-050000974</guid>
<pubDate>Tue, 05 Aug 2025 05:00:00 GMT</pubDate>
<description>Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine pro</description>
</item>
<item>
<title>Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-share-latest-magnetos-050000594</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-share-latest-magnetos-050000594</guid>
<pubDate>Tue, 13 May 2025 05:00:00 GMT</pubDate>
<description>Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be available virtually via live webcast. Capital Markets Day will</description>
</item>
<item>
<title>Annual General Meeting of Kuros Biosciences approves all resolutions</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/annual-general-meeting-kuros-biosciences-120100776</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/annual-general-meeting-kuros-biosciences-120100776</guid>
<pubDate>Tue, 15 Apr 2025 12:01:00 GMT</pubDate>
<description>Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2024 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and</description>
</item>
<item>
<title>Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-82-over-050000900</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-reports-82-over-050000900</guid>
<pubDate>Tue, 15 Apr 2025 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs™ sales increased by 79% to USD 28.4 million in Q1 2025 (Q1 2024: USD 15.8 million)Total Medical Device sales rose by 82% to USD 28.8 million (Q1 2024: USD 15.8 million) with monthly revenue surpassing USD 10.0 million for the first timeTotal Group EBITDA reached USD 2.0 million (Q1 2</description>
</item>
<item>
<title>Kuros Biosciences grows sales to CHF 75.6 million for 2024</title>
<link>https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-grows-sales-chf-060000210</link>
<guid isPermaLink="true">https://6ix.com/company/kuros-biosciences-ag/news/kuros-biosciences-grows-sales-chf-060000210</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 GMT</pubDate>
<description>Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million)Total Medical Device sales rose by 125% to CHF 75.6 million (2023: CHF 33.6 million)Total Group EBITDA reached CHF 2.2 million (2023: EBITDA loss of CHF (5.9) million), including the impairment, the group ended in a net loss of CHF (4.3) millionTotal Group adjusted E</description>
</item>
</channel>
</rss>